Central South Univ. LOXL2 compound 10q

Central South Univ. LOXL2 compound 10q: sourced facts only. name: "Structure-based optimization of 2-substituted pyridine-4-ylmethanamine scaffold led to the identification of 10q, exhibiting notable LOXL2 inhibitory activity with IC50 value of 79.38 nM, superior to the lead compound." [PMID:42241910]; target: "Structure-based optimization of 2-substituted pyridine-4-ylmethanamine scaffold led to the identification of 10q, exhibiting notable LOXL2 inhibitory activity with IC50 value of 79.38 nM, superior to the lead compound." [PMID:42241910]; developer: "Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, PR China; Hunan Key laboratory of Diagnostic and Therapeutic Drug Research for Chronic Diseases, Central South University, Changsha, PR China." [PMID:42241910]; stage: "In invasive melanoma cells, 10q dose-dependently inhibited proliferation, invasion, migration, and cell-matrix adhesion as well as attenuating focal adhesions (FAs) and stress fibers (SFs) formation." [PMID:42241910]